Fate Therapeutics, Inc. (FATE)
Largest Insider Buys in Sector
FATE Stock Price History Chart
FATE Stock Performance
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid …
Insider Activity of Fate Therapeutics, Inc.
Over the last 12 months, insiders at Fate Therapeutics, Inc. have bought $166,024 and sold $240,389 worth of Fate Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Fate Therapeutics, Inc. have bought $27.68M and sold $21.89M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Redmile Group, LLC () — $2.16M.
The last purchase of 44,630 shares for transaction amount of $166,024 was made by Redmile Group, LLC () on 2023‑12‑26.
List of Insider Buy and Sell Transactions, Fate Therapeutics, Inc.
| 2024-08-06 | Sale | director | 633 0.0005% | $4.23 | $2,678 | -26.57% | ||
| 2024-03-04 | Sale | Chief Financial Officer | 2,447 0.0027% | $7.77 | $19,013 | -46.89% | ||
| 2024-01-29 | Sale | Chief Financial Officer | 1,849 0.0017% | $5.00 | $9,245 | -31.29% | ||
| 2024-01-09 | Sale | President and CEO | 14,391 0.0145% | $4.37 | $62,889 | -11.33% | ||
| 2024-01-09 | Sale | Chief R&D Officer | 11,271 0.0114% | $4.38 | $49,367 | -11.33% | ||
| 2024-01-09 | Sale | General Counsel and Secretary | 10,874 0.0109% | $4.37 | $47,519 | -11.33% | ||
| 2024-01-09 | Sale | Chief Financial Officer | 7,028 0.0071% | $4.37 | $30,712 | -11.33% | ||
| 2024-01-02 | Sale | Chief Financial Officer | 5,182 0.0052% | $3.66 | $18,966 | +6.68% | ||
| 2023-12-26 | 44,630 0.0455% | $3.72 | $166,024 | +4.55% | ||||
| 2023-12-18 | Sale | Chief Financial Officer | 1,585 0.0018% | $3.50 | $5,548 | +22.91% | ||
| 2023-11-09 | Sale | General Counsel and Secretary | 24,363 0.0278% | $2.40 | $58,471 | +81.31% | ||
| 2023-08-18 | Sale | Chief Financial Officer | 4,718 0.0048% | $2.80 | $13,210 | +35.25% | ||
| 2023-08-04 | Sale | director | 632 0.0006% | $3.71 | $2,345 | -0.80% | ||
| 2023-07-05 | Sale | Chief Financial Officer | 5,182 0.0053% | $4.83 | $25,029 | -22.74% | ||
| 2023-07-05 | Sale | Chief Commercial Officer | 3,854 0.0039% | $4.87 | $18,769 | -22.74% | ||
| 2023-06-14 | Sale | director | 3,460 0.0036% | $5.58 | $19,307 | -28.91% | ||
| 2023-04-21 | 256,639 0.26% | $6.18 | $1.59M | -27.09% | ||||
| 2023-04-20 | 20,000 0.0204% | $5.99 | $119,800 | -24.29% | ||||
| 2023-04-18 | Sale | Chief Medical Officer | 2,532 0.0027% | $6.57 | $16,648 | -26.97% | ||
| 2023-04-14 | Sale | 302,339 0.2996% | $5.84 | $1.77M | -24.54% |
Insider Historical Profitability
| Redmile Group, LLC | 13180388 11.5725% | $1.68 | 8 | 1 | +12.66% | |
| NELSEN ROBERT | 2473188 2.1715% | $1.68 | 1 | 0 | <0.0001% | |
| ARCH VENTURE FUND VI LP | 10 percent owner | 2473188 2.1715% | $1.68 | 1 | 0 | <0.0001% |
| VENROCK ASSOCIATES V LP | 10 percent owner | 2473187 2.1715% | $1.68 | 1 | 0 | <0.0001% |
| Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 2473186 2.1715% | $1.68 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Redmile Group | $96.66M | 11.57 | 13.17M | 0% | +$0 | 0.99 | |
| The Vanguard Group | $72.75M | 8.71 | 9.91M | +6.65% | +$4.53M | <0.01 | |
| BlackRock | $66.79M | 7.99 | 9.1M | -18.84% | -$15.51M | <0.01 | |
| Boxer Capital, LLC | $60.3M | 7.22 | 8.22M | +1,543.18% | +$56.63M | 1.24 | |
| State Street | $58.99M | 7.06 | 8.04M | +331.63% | +$45.32M | <0.01 |